Skip to content
Bladder Preservation with Systemic Therapy Alone
Actinium-225 in Prostate Cancer
Triplet vs Doublet Therapy for mCSPC
Neuroendocrine/Small Cell Prostate Cancer
Updates in Testicular Cancer
A Primer on ctDNA Technologies
ctDNA Biomarkers to Drive Therapy
ctDNA (Liquid Biopsy for MRD) in the Curative Setting
Proteomics: The Promise for the Future
Exosomes in Diagnosis and Treatment
Use of Artificial Intelligence in Breast Cancer Diagnostics
The Integrative Breast Cancer Subtypes: From Relapse Prediction to Novel Targets
Multi-Cancer Early Detection (MCED)
Understanding Mechanisms of ADC Resistance: Lessons Learned and New Directions
Neoadjuvant Endocrine Therapy
Neoadjuvant Immunotherapy for Triple Negative Breast Cancer
Neoadjuvant Immunotherapy for HR+ Disease
Neoadjuvant with Antibody Drug Conjugates (ADC)
Improving and Optimizing Adjuvant Treatment for HER2+ Residual Disease
Strategies to Treat High Risk HR+, HER2 - Residual Disease (CDKi, IO, ADCs?)
Innovation in Tackling Triple Negative Residual Disease Following Preoperative KN-522 Regimen
Evaluating and Targeting Defects in DNA Repair
Who Needs Radiation Post Neoadjuvant Therapy
Novel Endocrine Therapies
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Ok 
